PHARMASHOTS NEWSWIRE

Mar 26, 2025  – Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – – Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – CARLSBAD, Calif.--(BUSINE

March 26, 2025 Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors / Clinical phase I study under development name BAY 3713372 initiated and first participant enrolled / MTAP deletions occur in approximately 10 to 30 percent

March 26, 2025 EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved CAPVAXIVE®&

March 26, 2025 Conexxence®** (denosumab-bnht) and Bomyntra®**(denosumab-bnht) received FDA approval for all indications of the reference products: Prolia®* (denosumab) and Xgeva®*(denosumab) respectively.  Fresenius’ operating company Fresenius Kabi reached a Global

Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) s

Mar 26, 2025 – FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo – – CABOMETYX is now the first and only systemic treatment that is FDA appr